After having been diagnosed with myeloma in 2019, Vincent Claus got in touch with MPE and joined the Taskforce. In 2022, he joined the Advocate Development Programme (ADP) and has since then been involved in many patient advocacy efforts such as SISAQOL-IMI. Recently with the support of MPE, he launched a specific support group for younger myeloma patients (European Young Myeloma Patients Group). His main fields of interest are the youngest myeloma population, lobbying for early(er) diagnosis and equal treatment approaches across Europe.
EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma patients
On 14 November 2024, the Committee for Medicinal Products for Human Use (CHMP) recommended adding a new indication for isatuximab, a monoclonal antibody treatment marketed by Sanofi as Sarclisa ®.…